Med tech business, Entia, has raised $12 million in a funding round to launch a virtual oncology solution.
Entia Library will allow patients to perform their own blood tests at home so remote healthcare teams can monitor and help manage the haematological toxicity of cancer treatment.
The financial round was led by UK growth capital investor BGF, with participation from existing seed investors, including Parkwalk and Sussex Place Ventures.
“Our approach at Entia is to empower patients with greater freedom whilst also equipping healthcare professionals with the insights to make more informed and personalised clinical decisions.” said Dr Toby Basey-Fisher, founder and CEO of Entia.
“This funding will enable us to put Liberty in the hands of patients and prepare to meet growing international demand for our solution”.
Since it was founded in 2015, Entia has built partnerships with leading healthcare institutions such as The Christie NHS Foundation Trust, to pioneer the introduction of new remote care solutions.
Moving healthcare services into the home has become a strategic priority not only for health systems but also pharmaceutical companies.
Pfizer UK recently announced its partnership with Entia in which it has committed to make Entia’s virtual monitoring service available in the UK for metastatic breast cancer patients in 2022, following regulatory approval.
At the heart of Entia’s Liberty service is a blood analyser that allows patients to perform a suite of blood tests in their own home. It is initially launching with the capability to help monitor haematological toxicity via a patient’s full blood count.
Results are seamlessly shared with healthcare professionals via Entia’s cloud network and integration tools. This approach creates new insights into how individuals are responding to care and subsequently may enable more personalised decisions to mitigate life-threatening complications.
Prior to this new investment, Entia has raised over $13 million to date, including major investment from Innovate UK as part of its Biomedical Catalyst programme.
